#ESMO26 | CAPItello-281 update: Capivasertib + abiraterone improves OS in PTEN-deficient mHSPC (HR 0.82; 57.4 vs 46.5 months), with sustained rPFS benefit.

Martin ZapataLaguado· @zapatalaguadomd · X·2026-10-23 20:53· 2 days agoScore70

Body · original

A promising first-line strategy! @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily#ProstateCancer

71 views · 0 likes · 1 repost · 0 replies

Conference abstracts

LBA56NCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281

https://esmocongress.esmo.org

Source: Martin ZapataLaguado · x.com